Dual probiotic strains suppress high fructose-induced metabolic syndrome.
OBJECTIVE
To investigate the effect of novel probiotics on the clinical characteristics of high-fructose induced metabolic syndrome.


METHODS
Male Wistar rats aged 4 wk were fed a 70% w/w high-fructose diet (n = 27) or chow diet (n = 9) for 3 wk to induce metabolic syndrome, the rats were then randomized into groups and administered probiotic [Lactobacillus curvatus (L. curvatus) HY7601 and Lactobacillus plantarum (L. plantarum) KY1032] at 10(9) cfu/d or 10(10) cfu/d or placebo by oral gavage for 3 wk. Food intake and body weight were measured once a week. After 6 wk, the rats were fasted for 12 h, then anesthetized with diethyl ether and sacrificed. Blood samples were taken from the inferior vena cava for plasma analysis of glucose, insulin, C-peptide, total-cholesterol, triglycerides and thiobarbituric acid-reacting substances. Real-time polymerase chain reaction was performed using mouse-specific Taqman probe sets to assess genes related to fatty acid β-oxidation, lipogenesis and cholesterol metabolism in the liver. Target gene expression was normalized to the housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase.


RESULTS
Rodents fed a high-fructose diet developed clinical characteristics of the metabolic syndrome including increased plasma glucose, insulin, triglycerides, total cholesterol and oxidative stress levels, as well as increased liver mass and liver lipids compared to chow fed controls. Probiotic treatment (L. curvatus HY7601 and L. plantarum KY1032) at high (10(10) cfu/d) or low dosage (10(9) cfu/d) lowered plasma glucose, insulin, triglycerides and oxidative stress levels. Only high-dose probiotic treatment reduced liver mass and liver cholesterol. Probiotic treatment reduced lipogenesis via down-regulation of SREBP1, FAS and SCD1 mRNA levels and increased β-oxidation via up-regulation of PPARα and CPT2 mRNA levels.


CONCLUSIONS
Probiotic L. curvatus HY7601 and L. plantarum KY1032 combined suppressed the clinical characteristics of high-fructose-induced metabolic syndrome, therefore, may provide a natural alternative for the treatment of diet-induced metabolic syndrome.
Korea Yakult Co., Ltd., Yongin, Gyeonggi 449-901, South Korea.
Do-Young
DY
Park
Young-Tae
YT
Ahn
Chul-Sung
CS
Huh
Robin A
RA
McGregor
Myung-Sook
MS
Choi
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002096:C-Peptide / Q000097:blood; D002784:Cholesterol / Q000097:blood; D004040:Dietary Carbohydrates / Q000009:adverse effects*; D004195:Disease Models, Animal; D005632:Fructose / Q000009:adverse effects*; D007328:Insulin / Q000097:blood; D007778:Lactobacillus / Q000145:classification*; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000209:etiology* / Q000517:prevention & control*; D018384:Oxidative Stress / Q000187:drug effects; D019936:Probiotics / Q000627:therapeutic use*; D051381:Rats; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D014280:Triglycerides / Q000097:blood
D001786:Blood Glucose; D002096:C-Peptide; D004040:Dietary Carbohydrates; D007328:Insulin; D017392:Thiobarbituric Acid Reactive Substances; D014280:Triglycerides; D005632:Fructose; D002784:Cholesterol
Dyslipidemia; Fasting glucose; Gut microbiota; High-fructose diet; Inflammation; Insulin resistance; Lactobacillus; Metabolic syndrome; Oxidative stress; Probiotic